Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma

Zhang,Xiubing; Hua,Lu; Yan,Daliang; Zhao,Fengbo; Liu,Jinxia; Zhou,Huiling; Liu,Jie; Wu,Miaomiao; Zhang,Chengliang; Chen,Yingying; Chen,Buyou; Hu,Baoying

doi:10.3892/or.2016.5167

Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma

Authors:
- Xiubing Zhang
- Lu Hua
- Daliang Yan
- Fengbo Zhao
- Jinxia Liu
- Huiling Zhou
- Jie Liu
- Miaomiao Wu
- Chengliang Zhang
- Yingying Chen
- Buyou Chen
- Baoying Hu
View Affiliations

Affiliations: Department of Oncology, Nantong Second People's Hospital, Nantong, Jiangsu 226001, P.R. China, Jiangsu Province Key Laboratory for Inﬂammation and Molecular Drug Target, Nantong University, Nantong, Jiangsu 226001, P.R. China, Basic Medical Research Centre, Medical College, Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Radiotherapy, Afﬁliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: October 13, 2016 https://doi.org/10.3892/or.2016.5167
Pages: 3456-3464

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Poly(C)‑binding protein 2 (PCBP2) is a member of the PCBP family, and plays an important role in post‑transcriptional and translational regulation of various signaling molecules through direct binding to single‑stranded poly(C) motifs. PCBP2 has been reported to play a critical role in the development of multiple human tumors. However, whether PCBP2 participates in hepatocellular carcinoma (HCC) development remains largely elusive. Herein, we showed that PCBP2 was upregulated in human HCC tissues and cell lines. Overexpression of PCBP2 predicted significantly worsened prognosis in HCC patients, suggesting that PCBP2 may serve as a prognostic marker of HCC. In addition, we found that depletion of PCBP2 inhibited HCC cell proliferation, accompanying the increase in the cyclin‑dependent kinase inhibitor p27 level. Moreover, we found that high expression of PCBP2 may contribute to sorafenib resistance in HCC cells, involving dysregulated expression of Bax and Bcl‑2 proteins. In conclusion, our results suggest that PCBP2 may serve as a prognostic marker and potential therapeutic target of HCC.

View Figures

View References

1	Tsochatzis EA, Meyer T and Burroughs AK: Hepatocellular carcinoma. N Engl J Med. 366:92–93; author reply 92–93. 2012. View Article : Google Scholar : PubMed/NCBI
2	Malek NP, Schmidt S, Huber P, Manns MP and Greten TF: The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int. 111:101–106. 2014.PubMed/NCBI
3	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
4	Finn RS: Development of molecularly targeted therapies in hepatocellular carcinoma: Where do we go now? Clin Cancer Res. 16:390–397. 2010. View Article : Google Scholar : PubMed/NCBI
5	Andino R, Böddeker N, Silvera D and Gamarnik AV: Intracellular determinants of picornavirus replication. Trends Microbiol. 7:76–82. 1999. View Article : Google Scholar : PubMed/NCBI
6	Blyn LB, Towner JS, Semler BL and Ehrenfeld E: Requirement of poly(rC) binding protein 2 for translation of poliovirus RNA. J Virol. 71:6243–6246. 1997.PubMed/NCBI
7	Collier B, Goobar-Larsson L, Sokolowski M and Schwartz S: Translational inhibition in vitro of human papillomavirus type 16 L2 mRNA mediated through interaction with heterogenous ribonucleoprotein K and poly(rC)-binding proteins 1 and 2. J Biol Chem. 273:22648–22656. 1998. View Article : Google Scholar : PubMed/NCBI
8	Tang FM, Li WM, Chen Y, Wang DM and Han J: Expression of hnRNP K in lung adenocarcinoma cells. Sichuan Da Xue Xue Bao Yi Xue Ban. 39:823–826. 2008.(In Chinese). PubMed/NCBI
9	He Y, Brown MA, Rothnagel JA, Saunders NA and Smith R: Roles of heterogeneous nuclear ribonucleoproteins A and B in cell proliferation. J Cell Sci. 118:3173–3183. 2005. View Article : Google Scholar : PubMed/NCBI
10	Zhou ZJ, Dai Z, Zhou SL, Fu XT, Zhao YM, Shi YH, Zhou J and Fan J: Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma. Int J Cancer. 132:1080–1089. 2013. View Article : Google Scholar : PubMed/NCBI
11	Liu Y, Gai L, Liu J, Cui Y, Zhang Y and Feng J: Expression of poly(C)-binding protein 1 (PCBP1) in NSCLC as a negative regulator of EMT and its clinical value. Int J Clin Exp Pathol. 8:7165–7172. 2015.PubMed/NCBI
12	Sean P, Nguyen JH and Semler BL: The linker domain of poly(rC) binding protein 2 is a major determinant in poliovirus cap-independent translation. Virology. 378:243–253. 2008. View Article : Google Scholar : PubMed/NCBI
13	Sean P, Nguyen JH and Semler BL: Altered interactions between stem-loop IV within the 5′ noncoding region of coxsackievirus RNA and poly(rC) binding protein 2: Effects on IRES-mediated translation and viral infectivity. Virology. 389:45–58. 2009. View Article : Google Scholar : PubMed/NCBI
14	Molinaro RJ, Jha BK, Malathi K, Varambally S, Chinnaiyan AM and Silverman RH: Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2′,5′-oligoadenylate synthetase from prostate cancer cells. Nucleic Acids Res. 34:6684–6695. 2006. View Article : Google Scholar : PubMed/NCBI
15	Han W, Xin Z, Zhao Z, Bao W, Lin X, Yin B, Zhao J, Yuan J, Qiang B and Peng X: RNA-binding protein PCBP2 modulates glioma growth by regulating FHL3. J Clin Invest. 123:2103–2118. 2013. View Article : Google Scholar : PubMed/NCBI
16	Lin X, Yang B, Liu W, Tan X, Wu F, Hu P, Jiang T, Bao Z, Yuan J, Qiang B, et al: Interplay between PCBP2 and miRNA modulates ARHGDIA expression and function in glioma migration and invasion. Oncotarget. 7:19483–19498. 2016.PubMed/NCBI
17	Hu CE, Liu YC, Zhang HD and Huang GJ: The RNA-binding protein PCBP2 facilitates gastric carcinoma growth by targeting miR-34a. Biochem Biophys Res Commun. 448:437–442. 2014. View Article : Google Scholar : PubMed/NCBI
18	Wan C, Gong C, Zhang H, Hua L, Li X, Chen X, Chen Y, Ding X, He S, Cao W, et al: β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression. Cancer Lett. 373:67–76. 2016. View Article : Google Scholar : PubMed/NCBI
19	Fukushi S, Okada M, Kageyama T, Hoshino FB, Nagai K and Katayama K: Interaction of poly(rC)-binding protein 2 with the 5′-terminal stem loop of the hepatitis C-virus genome. Virus Res. 73:67–79. 2001. View Article : Google Scholar : PubMed/NCBI
20	Tingting P, Caiyun F, Zhigang Y, Pengyuan Y and Zhenghong Y: Subproteomic analysis of the cellular proteins associated with the 3′ untranslated region of the hepatitis C virus genome in human liver cells. Biochem Biophys Res Commun. 347:683–691. 2006. View Article : Google Scholar : PubMed/NCBI
21	Wang L, Jeng KS and Lai MM: Poly(C)-binding protein 2 interacts with sequences required for viral replication in the hepatitis C virus (HCV) 5′ untranslated region and directs HCV RNA replication through circularizing the viral genome. J Virol. 85:7954–7964. 2011. View Article : Google Scholar : PubMed/NCBI
22	Shukla RS, Qin B, Wan YJ and Cheng K: PCBP2 siRNA reverses the alcohol-induced pro-fibrogenic effects in hepatic stellate cells. Pharm Res. 28:3058–3068. 2011. View Article : Google Scholar : PubMed/NCBI
23	Leidgens S, Bullough KZ, Shi H, Li F, Shakoury-Elizeh M, Yabe T, Subramanian P, Hsu E, Natarajan N, Nandal A, et al: Each member of the poly-r(C)-binding protein 1 (PCBP) family exhibits iron chaperone activity toward ferritin. J Biol Chem. 288:17791–17802. 2013. View Article : Google Scholar : PubMed/NCBI
24	Wang Y, Wang Y, Xiang J, Ji F, Deng Y, Tang C, Yang S, Xi Q, Liu R and Di W: Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer. Cancer Lett. 343:6–13. 2014. View Article : Google Scholar : PubMed/NCBI
25	Wang Y, Liu F, Mao F, Hang Q, Huang X, He S, Wang Y, Cheng C, Wang H, Xu G, et al: Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration. J Biol Chem. 288:9028–9034. 2013. View Article : Google Scholar : PubMed/NCBI
26	Akiba N, Hayakawa I, Keh ES and Watanabe A: Antifungal effects of a tissue conditioner coating agent with TiO₂ photocatalyst. J Med Dent Sci. 52:223–227. 2005.PubMed/NCBI
27	Cragg MS and Glennie MJ: Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 103:2738–2743. 2004. View Article : Google Scholar : PubMed/NCBI
28	Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
29	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
30	Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y and Ohnishi K: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 56:918–928. 1985. View Article : Google Scholar : PubMed/NCBI
31	Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW and Weitz J: Hepatocellular carcinoma: Current management and perspectives for the future. Ann Surg. 253:453–469. 2011. View Article : Google Scholar : PubMed/NCBI
32	Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, et al: miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 140:652–665. 2010. View Article : Google Scholar : PubMed/NCBI
33	Koganti S, Clark C, Zhi J, Li X, Chen EI, Chakrabortty S, Hill ER and Bhaduri-McIntosh S: Cellular STAT3 functions via PCBP2 to restrain Epstein-Barr Virus lytic activation in B lymphocytes. J Virol. 89:5002–5011. 2015. View Article : Google Scholar : PubMed/NCBI
34	Midorikawa Y, Yamamoto S, Ishikawa S, Kamimura N, Igarashi H, Sugimura H, Makuuchi M and Aburatani H: Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene. 25:5581–5590. 2006. View Article : Google Scholar : PubMed/NCBI
35	Luo X and Feng GS: VEGFA genomic amplification tailors treatment of HCCs with sorafenib. Cancer Discov. 4:640–641. 2014. View Article : Google Scholar : PubMed/NCBI